Mermaid Medical A/S

New York, May 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Interventional Oncology Market by Product, Procedure, Cancer, Enduser - Global Forecast to 2026" - However, unfavorable reimbursement scenarios in some countries is hampering the growth of this market.The recent COVID-19 global pandemic has also impacted the interventional oncology market.Demand from the main end-users has declined as key regions and countries have imposed social distancing rules and lockdowns.This impact is expected to be short-term, and no adverse effects are to be foreseen after the market gradually reopens.The embolization devices segment to witness the highest share in interventional oncology market, by product, during the forecast period.In 2020, embolization devices accounted for a share of the interventional oncology market.Embolization devices include non-radioactive embolic agents and radioembolic agents.Although these devices are primarily employed to treat hepatocellular carcinoma, their use has been widely extended to various other forms of cancer.These devices are used when tumors cannot be treated using ablation techniques and in cases where the tumor size is large.They are also used in palliative procedures and as a pre-operative procedure to improve the outcome of liver resection.Embolic agents include radioembolic agents and non-radioactive embolic agents.Non-radioactive embolic agents include gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol (PVA).Gelatin foam is a non-radioactive embolic agent and is considered a temporary embolic agent whose effect is relatively shorter. Other non-radioactive embolic agents are considered permanent agents whose effects are seen for a longer period.The liver cancer accounted for the largest share of the interventional oncology market, by application, in 2020.Liver cancer accounted for the largest share of the interventional oncology market in 2020.Interventional oncology plays a crucial role in treating liver cancer, as removing the tumor with surgery may not leave the tissue healthy enough for effective liver functioning.Thus, primary liver tumors or liver tumors resulting from metastatic cancers can effectively be treated using interventional oncology procedures. Owing to this, more than half of all treatments for primary and metastatic liver cancer are conducted using interventional oncology.The large share of this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities to develop advanced liver cancer therapies using interventional oncology. In addition, initiatives in the form of grants and funding for the development of advanced therapies using interventional oncology also fuel market growth.The Hospitals & diagnostic centers segment accounted for the largest share of the interventional oncology market, by end users, in 2020Hospitals & diagnostic centers accounted for the largest share of the interventional oncology market in 2020.The availability of state-of-the-art facilities for treating disorders and injuries and trained personnel has ensured a steady demand for hospital-based care.The inflow of patients is considerably higher in hospitals than in other healthcare settings, which is another key driver for market growth.Hospitals routinely conduct a wide range of surgical procedures, and most of these surgeries are performed in hospital in-patient settings. Growth in this segment is primarily attributed to the growing number of minimally invasive surgeries and electrosurgery procedures performed in hospitals and the adoption of robotic surgery.The Asia Pacific market to grow at the highest CAGR during the forecast period.The interventional oncology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Government efforts to increased funding , supportive regulations for the development and commercialization of advanced interventional oncology products, rising healthcare expenditure, increasing number of hospitals and clinics in India and China, expanding research base across India, China, and Japan, and the increasing incidence of surgeries are the major factors driving the growth of the APAC interventional oncology market.Breakdown of supply-side primary interviews:• By Company Type: Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%• By Designation: C-level: 10%, D-level: 14%, and Others: 76%• By Region: North America: 45%, Europe: 24%, APAC: 20%, Latin America: 7%, and the Middle East & Africa: 4%The major players operating in the interventional oncology market are Medtronic (Ireland), Boston Scientific (US), BD (US), Terumo (Japan), Merit Medical (US), AngioDynamics (US), J&J (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris Medical (US), Instylla (US), Trisalus Lifesciences (US), Profound Medical Corp (Canada), Sirtex (US), Accuray (US), Baylis Medical (Canada), and ALPINION MEDICAL SYSTEMS (South Korea).Research CoverageThis report studies the interventional oncology market based on the product, procedure, cancer type, end user, and region.The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders.Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).Key Benefits of Buying the ReportThis report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the interventional oncology market, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.Read the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________

High burden of orthopedic cancers is stimulating enhanced biopsy systems deployment to enable timely treatment Fact.MR, Rockville MD: The global bone biopsy systems market study being conducted by market research firm Fact.MR projects a positive expansion outlook for 2021 and beyond. As the coronavirus pandemic’s onslaught recedes, hospitals and clinics are reverting to their pre-pandemic routine, leading to a resumption in bone biopsy procedures, thus restoring demand. As the global geriatric population exponentially surges, prevalence of osteoporosis and low bone mass has risen to 52 million by 2010, and reached 51 million active cases by 2020. This means that over half of all Americans aged above 50 years are at an elevated risk of developing osteoporosis of the hip. According to the World Health Organization, approximately 1.71 billion have musculoskeletal conditions worldwide. Amid such a scenario, demand for advanced bone biopsy procedures is becoming the need of the hour. According to Fact.MR’s study, growth in the bone biopsy systems market is underpinned by rising prevalence of bone related disorders, which is facilitating enhanced research and development to introduce technologically advanced and precise therapeutics. Since the beginning of the previous decade, breakthroughs such as intraosseous medicine is ushering in a much-needed change in bone diagnostics, especially in bone marrow procedures. “With increased prevalence of sedentary living, chronic bone disorders are only set to incline, prompting patients to seek effective treatment. This is providing immense opportunities for prominent bone biopsy manufacturers to tap lucrative markets, especially in the developing world,” remarks the Fact.MR analyst. For more insights into the Market, Request a Sample of this Report Key Takeaways from Fact.MR’s Bone Biopsy Systems Study By type, needle biopsy is expected to remain most prominent, given the rising demand for precise surgeries Cancer detection constitutes the primary indication purpose behind deploying bone biopsy systems By end-user, hospitals to represent the largest clientele for bone biopsy systems US to remain a promising market, attributed to rising incidence of arthritis and osteoarthritis Treatment for secondary bone cancer to stimulate enhanced bone biopsy systems adoption in the UK Rising osteoporosis cases is fueling bone biopsy treatment across Germany and France India & China to attract huge investments, attributed to increased vulnerability to joint fractures among adults in urban areas Bone Biopsy Market- Prominent Drivers Growing incidence of bone related cancers is stimulating demand for advanced bone biopsy systems Emergence of multiple detection approaches, including those involving advanced imaging techniques, is driving increased sales Rising international level collaborations to facilitate enhanced bone disorders research is providing a wide ground for key bone biopsy systems manufacturers Bone Biopsy Market- Key Restraints Asymmetrical healthcare infrastructure in developing countries is restricting uptake of bone biopsy systems amid financial constraints Limited awareness concerning effective bone disorders diagnosis among patients leads to reduced screening procedures, limiting sales Discover more about the bone biopsy systems market with figures, data tables and the table of contents. You will also find detailed market segmentation on Competitive Landscape Merit Medical Systems, Stryker Corporation, Argon Medical Devices Inc., Becton Dickinson & Company, Teleflex Incorporated, Laurane Medical, Mermaid Medical A/S and Remington Medical are some prominent bone biopsy systems manufacturers profiled in Fact.MR’s study. Offering the latest biopsy equipment remains the core strategy of most of the aforementioned market players. Merit Medical Systems is a pioneer in the bone biopsy domain, offering a wide range of biopsy systems. Some of its products include the HuntingtonTM Bone Biopsy System, KensingtonTM Bone Biopsy System, MadisonTM Bone Biopsy System, and the WestbrookTM Bone Biopsy System among others. Additionally, it also offers the PrestonTM Bone Biopsy Accessories and BiopSafe® Biopsy Sample Systems respectively. Likewise, Stryker Corporation offers an entire range of bone biopsy kits which are compatible with their 8, 10 and 11 gauge needles. The coaxial design allows for biopsy collection of a core sample within the vertebral body. The needle’s syringe measures 3cc and features a rotating handle for greater flexibility. More Insights on the Bone Biopsy Systems Market In its latest report, Fact.MR offers unbiased analysis of the global bone biopsy systems market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of type (needle biopsy and open biopsy), indication (cancer, bone infection, osteoporosis, chronic kidney disease and others) and end user (hospitals, specialty clinics, and ambulatory surgical centers) across seven regions (North America, Latin America, Western Europe, Eastern Europe, Japan, APEJ and Middle East & Africa) Request for No-Obligation Table of Content Explore Fact.MR’s Coverage on the Healthcare Domain Pleural Catheters Market: Fact.MR’s extensive coverage on the pleural catheters market provides detailed assessment on the key market dynamics, including drivers, trends, and opportunities expected to present themselves throughout the course of the market’s expansion trajectory. Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compound annual growth rate (CAGR) are explained in Fact MR’s study in a comprehensive manner. Dyslipidemia Therapeutics Market: The global dyslipidemia therapeutics market research report compiled by Fact.MR elaborates on the key expansion dynamics anticipated to play a role in its future growth. Market statistics have been presented across key segments spread over prominent geographies while also incorporating an in-depth competition landscape analysis to provide an unbiased and realistic market growth picture. Lewy Body Dementia Market: The Fact.MR report on Lewy body dementia treatment market provides an exhaustive analysis of the Lewy body dementia treatment market roadmap for the upcoming decade. The report on Lewy body dementia treatment market also offers a comprehensive segmental analysis, wherein all the lucrative segments are given in detail in tandem with their performance during the assessment period. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Follow Us: LinkedIn | Twitter Market Intelligence Services: Marketngage Corporate Headquarter: Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates Source: Fact.MR